Aikangte Snags ￥100M in Series A Funding Round

According to VCBeat, Aikangte Medical Technology Co., Ltd. ("Aikangte"), a R&D and production company dedicated to the field of ophthalmology and optometry, has recently completed a Series A round of financing, with a total amount over 100 million yuan combining with its locked-in Series A+ round. 

The latest round was led by Sequoia Capital China, with participation from Sherpa Venture Capital, Fosun Capital, Green Pine Capital, YuanBio Venture Capital, Hengqin Financial Investment, etc. The funds raised will be used to accelerate the development, clinical researches and registration of Aikangte's various optometry products.

Aikangte is a medical device manufacturer in the field of optometry. Its optometry solutions mainly involve prevention and control of myopia among adolescents, correction of vision for adults, a complete series of contact lens care products and optometry equipment. A number of devices developed by Aikangte, including sclera lens, are the first launch of similar products in the domestic market, which fill the industry gap.

Aiming at vision correction and ocular surface diseases (OSD) in adults, Aikangte is about to launch the rigid gas-permeable (RGP) contact lens and the first scleral lens in China. Scleral lenses will fill the gap in the domestic industry. Patients with moderate to severe keratoconus, eyelid insufficiency caused by various reasons, postoperative ocular surface repair, such as corneal transplantation and trauma, and vision correction have rigid demands for sclera lens. For irregular astigmatism and moderate to severe dry eye caused by various reasons, wearing sclera lens is the preferred method of correction and treatment.

Sequoia Capital China is a VC firm focused on seed-stage, mid-stage, late-stage, and growth investments in the fintech sector.

Formed in September 2005, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models, including Alibaba, VIPshop.com, Sina.com, Didi, JD.com, Ourpalm, Qihoo 360, Jumei, Momo, and so on.

Founded in 2018 and is headquartered in Beijing, China, Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where the company has established robust portfolio sources, lasting value-adding cooperation and relationships, as well as mature all-cycle services with key resources.